Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02248207

Enrollment

1293

Registered

2014-09-25

Start date

2003-01-31

Completion date

Unknown

Last updated

2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's disease under routing conditions

Interventions

DRUGPramipexole

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with Parkinson's disease who present to the specialist neurologist practice for the first time without or with referral and who are planned to receive or either be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can be included in this observational study

Exclusion criteria

* Neurologists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Design outcomes

Primary

Measure	Time frame
Global Assessment of efficacy by investigator on a 4-point scale	after 8 weeks
Change from Baseline in actual Parkinson symptoms	Baseline, after 8 weeks
Global Assessment of tolerability by investigator on a 4-point scale	after 8 weeks

Secondary

Measure	Time frame
Number of patients with adverse drug reactions	up to 8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026